Contact
Please use this form to send email to PR contact of this press release:
Opiant Pharmaceuticals, Inc., Receives $2.5 Million Milestone Payment Following Adapt Pharma Limited’s First Commercial Sale of NARCAN® (Naloxone Hydrochloride) Nasal Spray in the U.S.
TO: